 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does AMPHOTERICIN B increase or decrease the risk of hip fracture?"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_extracts) FUNC: {
  "name": "relevant_extracts",
  "to": "",
  "arguments": {
    "query": "Does AMPHOTERICIN B increase the risk of hip fracture?",
    "filter_drugs": [
      "AMPHOTERICIN B"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_extracts) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: AMPHOTERICIN B: adverse_reactions_table: <table width="100%"><col width="42%"/><col width="58%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " 
valign="top"><paragraph><content styleCode="bold">Adverse Events <sup>a</sup>with an Incidence of &#x2265;3% (N=556) </content></paragraph></td></tr><tr><td styleCode="Lrule Botrule " 
valign="top"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">Percentage (%)
of Patients</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Chills</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>18 AMPHOTERICIN B: 
adverse_reactions_table: </paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Fever</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>14</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Increased Serum Creatinine</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Multiple Organ Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>9</paragraph></td></tr><tr><td AMPHOTERICIN B: adverse_reactions_table: styleCode="Lrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" 
styleCode="Rrule " valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Respiratory Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Dyspnea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign=" AMPHOTERICIN B: adverse_reactions_table: top"><paragraph>Sepsis</paragraph></td><td align="center" styleCode="Rrule "
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Diarrhea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Cardiac Arrest</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Hypertension</paragraph></         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET ® does not distinguish 
amphotericin B that is complexed with the phospholipids of ABELCET ® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET ® are 
nonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET ® , resulting in less than proportional increases in blood concentrations of amphotericin B over a 
dose range of 0.6-5 mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET ® and amphotericin B desoxycholate are: 
Pharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET ® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET ® 5 mg/kg/day for 5-7
days Mean ± SD Amphotericin B 0.6 mg/kg/day for 42 days a Mean ± SD Peak Concentration ( μg/mL) 1.7 ± 0.8 (n=10) b 1.1 ± 0.2 (n=5) Concentration at End of Dosing Interval (μg/mL) 0.6 ± 0.3 (n=10 b 0.4
± 0. AMPHOTERICIN B: clinical_pharmacology: 2 (n=5) Area Under Blood Concentration-Time Curve (AUC 0-24h ) (μg*h/mL) 14.0 ± 7.0 (n=14) b,c 17.1 ± 5 (n=5) Clearance (mL/h*kg) 436.0.± 188.5 (n=14) b,c 
38.0 ± 15 (n=5) Apparent Volume of Distribution (Vd area ) (L/kg) 131.0.± 57.7 (n=8) c 5.0.± 2.8 (n=5) Terminal Elimination Half-Life (h) 173.4 ± 78.0 (n=8) c 91.1 ± 40.9 (n=5) Amount Excreted in 
Urine Over 24 h After Last Dose (% of dose) d 0. AMPHOTERICIN B: clinical_pharmacology: 9 ± 0.4 (n=8) c 9.6 ± 2.5 (n=8) a Data from patients with mucocutaneous leishmaniasis. Infusion rate was 0.25 
mg/kg/h. b Data from studies in patients with cytologically proven cancer being treated with chemotherapy or neutropenic patients with presumed or proven fungal infection. Infusion rate was 2.5 
mg/kg/h. c Data from patients with mucocutaneous leishmaniasis. Infusion rate was 4 mg/kg/h. d Percentage of dose excreted in 24 hours after last dose. The large volume of distribution and high 
clearance from blood of amphotericin B after the admistration of ABELCET ® probably reflect uptake by tissues. The long terminal elimination half-life probably reflects a slow redistribution from 
tissues. AMPHOTERICIN B: clinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased 
approximately 34% from day 1 after the administration of ABELCET ® 5 mg/kg/day for 7 days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET ® has not been studied. Tissue 
concentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET ® at 5.3 mg/kg/day: Concentration in Human Tissues Organ 
Amphotericin B Tissue Concentration (µg/g) Spleen 290.0 Lung 222.0 Liver 196.0 Lymph Node 7.6 Kidney 6.9 Heart 0 5. Brain 1. AMPHOTERICIN B: clinical_pharmacology: 6 This pattern of distribution is 
consistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET ® administration were observed in the liver, spleen, and lung; however, 
the relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET ® is unknown. Special Populations Hepatic Impairment: The effect of hepatic 
impairment on the disposition of ABELCET ® is not known. Renal Impairment: The effect of renal impairment on the disposition of ABELCET ® is not known. The effect of dialysis on the elimination of 
ABELCET ® has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly 
Patients: The pharmacokinetics and pharmacodynamics of pediatric patients (≤16 years of age) and elderly patients (≥65 years of age) have not been studied.         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology_table: <table width="100%"><col width="50%"/><col width="50%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " 
valign="top"><paragraph><content styleCode="bold">Concentration in Human Tissues</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph> 
<content styleCode="bold">Organ</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">Amphotericin 
B</content></paragraph><paragraph><content styleCode="bold">Tissue Concentration (&#xB5;g/g)</content></paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Spleen</paragraph></td><td align="center" styleCode=" AMPHOTERICIN B: clinical_pharmacology_table: Rrule " valign="top"><paragraph>290.0</paragraph></td></tr><tr><td 
styleCode="Lrule " valign="top"><paragraph>Lung</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>222.0</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Liver</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>196.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Lymph 
Node</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>7. AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Kidney</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>6.9</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Heart 
0</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5.</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Brain</paragraph></td><td 
align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1. AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr></tbody></table>         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_set_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: pharm_class_epc         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: adverse_reactions: ADVERSE REACTIONS The total safety data base is composed of 921 patients treated with ABELCET ® (5 patients were enrolled twice and counted as separate 
patients), of whom 775 were treated with 5 mg/kg/day. Of these 775 patients, 194 patients were treated in four comparative studies; 25 were treated in open-label, non-comparative studies; and 556 
patients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the 556 patients treated with 
ABELCET ® , 9% discontinued treatment due to adverse events regardless of presumed relationship to study drug. In general, the adverse events most commonly reported with ABELCET ® were transient 
chills and/or fever during infusion of the drug. AMPHOTERICIN B: adverse_reactions: Adverse Events a with an Incidence of ≥3% (N=556) Adverse Event Percentage (%) of Patients Chills 18 Fever 14 
Increased Serum Creatinine 11 Multiple Organ Failure 11 Nausea 9 Hypotension 8 Respiratory Failure 8 Vomiting 8 Dyspnea 7 Sepsis 7 Diarrhea 6 Headache 6 Cardiac Arrest 6 Hypertension 5 Hypokalemia 5 
Infection 5 Kidney Failure 5 Pain 5 Thrombocytopenia 5 Anemia 4 Hyperbilirubinemia 4 Gastrointestinal Hemorrhage 4 Leukopenia 4 Rash 4 Respiratory Disorder 4 Chest Pain 3 Nausea and Vomiting 3 a The 
causal association between these adverse events and ABELCET ® is uncertain. AMPHOTERICIN B: adverse_reactions: The following adverse events have also been reported in patients using ABELCET ® in 
open-label, uncontrolled clinical studies. The causal association between these adverse events and ABELCET ® is uncertain. Body as a whole: malaise, weight loss, deafness, injection site reaction 
including inflammation Allergic: bronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis,
tachypnea, thrombophlebitis, pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. AMPHOTERICIN B: adverse_reactions: Dermatological: maculopapular rash,
pruritus, exfoliative dermatitis, erythema multiforme Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, 
diarrhea, hepatomegaly, cholangitis, cholecystitis Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia Musculoskeletal: myasthenia, including bone, muscle, and 
joint pains Neurologic: convulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome 
and other neurologic symptoms Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria Serum electrolyte         
SOURCE:AMPHOTERICIN B label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          )  DO-NOT-KNOW
*(FDAHandler)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does AMPHOTERICIN B increase the risk of hip fracture?",
    "drug": "AMPHOTERICIN B"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does AMPHOTERICIN B increase the risk of hip 
fracture?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does AMPHOTERICIN B increase or decrease the risk of hip fracture?"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_extracts) FUNC: {
  "name": "relevant_extracts",
  "to": "",
  "arguments": {
    "query": "Does AMPHOTERICIN B increase the risk of hip fracture?",
    "filter_drugs": [
      "AMPHOTERICIN B"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_extracts) (=>          ) (X           )       (          ) 
CONTENT: AMPHOTERICIN B: adverse_reactions_table: <table width="100%"><col width="42%"/><col width="58%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " 
valign="top"><paragraph><content styleCode="bold">Adverse Events <sup>a</sup>with an Incidence of &#x2265;3% (N=556) </content></paragraph></td></tr><tr><td styleCode="Lrule Botrule " 
valign="top"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">Percentage (%)
of Patients</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Chills</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>18 AMPHOTERICIN B: 
adverse_reactions_table: </paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Fever</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>14</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Increased Serum Creatinine</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Multiple Organ Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>11</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>9</paragraph></td></tr><tr><td AMPHOTERICIN B: adverse_reactions_table: styleCode="Lrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" 
styleCode="Rrule " valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Respiratory Failure</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>8</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Dyspnea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign=" AMPHOTERICIN B: adverse_reactions_table: top"><paragraph>Sepsis</paragraph></td><td align="center" styleCode="Rrule "
valign="top"><paragraph>7</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Diarrhea</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Cardiac Arrest</paragraph></td><td align="center" styleCode="Rrule " 
valign="top"><paragraph>6</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Hypertension</paragraph></         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET ® does not distinguish 
amphotericin B that is complexed with the phospholipids of ABELCET ® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET ® are 
nonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET ® , resulting in less than proportional increases in blood concentrations of amphotericin B over a 
dose range of 0.6-5 mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET ® and amphotericin B desoxycholate are: 
Pharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET ® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET ® 5 mg/kg/day for 5-7
days Mean ± SD Amphotericin B 0.6 mg/kg/day for 42 days a Mean ± SD Peak Concentration ( μg/mL) 1.7 ± 0.8 (n=10) b 1.1 ± 0.2 (n=5) Concentration at End of Dosing Interval (μg/mL) 0.6 ± 0.3 (n=10 b 0.4
± 0. AMPHOTERICIN B: clinical_pharmacology: 2 (n=5) Area Under Blood Concentration-Time Curve (AUC 0-24h ) (μg*h/mL) 14.0 ± 7.0 (n=14) b,c 17.1 ± 5 (n=5) Clearance (mL/h*kg) 436.0.± 188.5 (n=14) b,c 
38.0 ± 15 (n=5) Apparent Volume of Distribution (Vd area ) (L/kg) 131.0.± 57.7 (n=8) c 5.0.± 2.8 (n=5) Terminal Elimination Half-Life (h) 173.4 ± 78.0 (n=8) c 91.1 ± 40.9 (n=5) Amount Excreted in 
Urine Over 24 h After Last Dose (% of dose) d 0. AMPHOTERICIN B: clinical_pharmacology: 9 ± 0.4 (n=8) c 9.6 ± 2.5 (n=8) a Data from patients with mucocutaneous leishmaniasis. Infusion rate was 0.25 
mg/kg/h. b Data from studies in patients with cytologically proven cancer being treated with chemotherapy or neutropenic patients with presumed or proven fungal infection. Infusion rate was 2.5 
mg/kg/h. c Data from patients with mucocutaneous leishmaniasis. Infusion rate was 4 mg/kg/h. d Percentage of dose excreted in 24 hours after last dose. The large volume of distribution and high 
clearance from blood of amphotericin B after the admistration of ABELCET ® probably reflect uptake by tissues. The long terminal elimination half-life probably reflects a slow redistribution from 
tissues. AMPHOTERICIN B: clinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased 
approximately 34% from day 1 after the administration of ABELCET ® 5 mg/kg/day for 7 days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET ® has not been studied. Tissue 
concentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET ® at 5.3 mg/kg/day: Concentration in Human Tissues Organ 
Amphotericin B Tissue Concentration (µg/g) Spleen 290.0 Lung 222.0 Liver 196.0 Lymph Node 7.6 Kidney 6.9 Heart 0 5. Brain 1. AMPHOTERICIN B: clinical_pharmacology: 6 This pattern of distribution is 
consistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET ® administration were observed in the liver, spleen, and lung; however, 
the relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET ® is unknown. Special Populations Hepatic Impairment: The effect of hepatic 
impairment on the disposition of ABELCET ® is not known. Renal Impairment: The effect of renal impairment on the disposition of ABELCET ® is not known. The effect of dialysis on the elimination of 
ABELCET ® has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly 
Patients: The pharmacokinetics and pharmacodynamics of pediatric patients (≤16 years of age) and elderly patients (≥65 years of age) have not been studied.         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: clinical_pharmacology_table: <table width="100%"><col width="50%"/><col width="50%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " 
valign="top"><paragraph><content styleCode="bold">Concentration in Human Tissues</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph> 
<content styleCode="bold">Organ</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">Amphotericin 
B</content></paragraph><paragraph><content styleCode="bold">Tissue Concentration (&#xB5;g/g)</content></paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Spleen</paragraph></td><td align="center" styleCode=" AMPHOTERICIN B: clinical_pharmacology_table: Rrule " valign="top"><paragraph>290.0</paragraph></td></tr><tr><td 
styleCode="Lrule " valign="top"><paragraph>Lung</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>222.0</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Liver</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>196.0</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Lymph 
Node</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>7. AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr><tr><td styleCode="Lrule " 
valign="top"><paragraph>Kidney</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>6.9</paragraph></td></tr><tr><td styleCode="Lrule " valign="top"><paragraph>Heart 
0</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5.</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Brain</paragraph></td><td 
align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1. AMPHOTERICIN B: clinical_pharmacology_table: 6</paragraph></td></tr></tbody></table>         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: spl_set_id         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: openfda: pharm_class_epc         
SOURCE:AMPHOTERICIN B label


CONTENT: AMPHOTERICIN B: adverse_reactions: ADVERSE REACTIONS The total safety data base is composed of 921 patients treated with ABELCET ® (5 patients were enrolled twice and counted as separate 
patients), of whom 775 were treated with 5 mg/kg/day. Of these 775 patients, 194 patients were treated in four comparative studies; 25 were treated in open-label, non-comparative studies; and 556 
patients were treated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the 556 patients treated with 
ABELCET ® , 9% discontinued treatment due to adverse events regardless of presumed relationship to study drug. In general, the adverse events most commonly reported with ABELCET ® were transient 
chills and/or fever during infusion of the drug. AMPHOTERICIN B: adverse_reactions: Adverse Events a with an Incidence of ≥3% (N=556) Adverse Event Percentage (%) of Patients Chills 18 Fever 14 
Increased Serum Creatinine 11 Multiple Organ Failure 11 Nausea 9 Hypotension 8 Respiratory Failure 8 Vomiting 8 Dyspnea 7 Sepsis 7 Diarrhea 6 Headache 6 Cardiac Arrest 6 Hypertension 5 Hypokalemia 5 
Infection 5 Kidney Failure 5 Pain 5 Thrombocytopenia 5 Anemia 4 Hyperbilirubinemia 4 Gastrointestinal Hemorrhage 4 Leukopenia 4 Rash 4 Respiratory Disorder 4 Chest Pain 3 Nausea and Vomiting 3 a The 
causal association between these adverse events and ABELCET ® is uncertain. AMPHOTERICIN B: adverse_reactions: The following adverse events have also been reported in patients using ABELCET ® in 
open-label, uncontrolled clinical studies. The causal association between these adverse events and ABELCET ® is uncertain. Body as a whole: malaise, weight loss, deafness, injection site reaction 
including inflammation Allergic: bronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis,
tachypnea, thrombophlebitis, pulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. AMPHOTERICIN B: adverse_reactions: Dermatological: maculopapular rash,
pruritus, exfoliative dermatitis, erythema multiforme Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, 
diarrhea, hepatomegaly, cholangitis, cholecystitis Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia Musculoskeletal: myasthenia, including bone, muscle, and 
joint pains Neurologic: convulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome 
and other neurologic symptoms Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria Serum electrolyte         
SOURCE:AMPHOTERICIN B label

 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "Does AMPHOTERICIN B increase or decrease the risk of hip fracture?"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(relevant_search_extracts) FUNC: {
  "name": "relevant_search_extracts",
  "to": "",
  "arguments": {
    "query": "Does AMPHOTERICIN B increase the risk of hip fracture?",
    "drug": "AMPHOTERICIN B"
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(relevant_search_extracts) (=>          ) (X           )       (          ) No relevant extracts found for Does AMPHOTERICIN B increase the risk of hip 
fracture?
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) I have attempted to obtain information regarding the effect of 
Amphotericin B on the risk of hip fracture by consulting FDAHandler. However, it appears that there is no response from FDAHandler, which prevents me from providing a reliable answer based on FDA 
label data.

Therefore, my final answer is DO-NOT-KNOW, as the FDA label data does not specify whether Amphotericin B increases or decreases the risk of hip fracture. Without this specific information, I cannot 
provide a definitive answer to your question.
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(          ) (=>       LLM) (X           )       (          ) 
        Do one of the following:

        1. If you intend to ask a question to FDAAgent:
            Please use the 'add_recipient' tool/function-call
            and specify FDAAgent as your `intended_recipient`.
            DO NOT REPEAT your original message; ONLY specify the 
            `intended_recipient` via this tool/function-call.
        2. If you are ready to have the critic check your answer,
            do so with the `final_answer` tool/function, as I have requested.
        3. If the critic is satisfied and you intend to submit your final answer,
            answer as I have requested, making sure to mark that you are done as usual.

        When you have decided and stated your answer (or lack of one), you must
        ALWAYS specify that you are done using the usual code.

        DO NOT simply acknowldedge these instructions. If you have nothing
        else to say, you MUST EXIT IMMEDIATELY by stating that you are done
        with the usual code (as in #3).
        
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(add_recipient) FUNC: {
  "name": "add_recipient",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) I have attempted to obtain information regarding the effect of 
Amphotericin B on the risk of hip fracture by consulting FDAHandler. However, it appears that there is no response from FDAHandler, which prevents me from providing a reliable answer based on FDA 
label data.

Therefore, my final answer is DO-NOT-KNOW, as the FDA label data does not specify whether Amphotericin B increases or decreases the risk of hip fracture. Without this specific information, I cannot 
provide a definitive answer to your question.
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) I have attempted to obtain information regarding the effect of Amphotericin B on the risk of hip 
fracture by consulting FDAHandler. However, it appears that there is no response from FDAHandler, which prevents me from providing a reliable answer based on FDA label data.

Therefore, my final answer is DO-NOT-KNOW, as the FDA label data does not specify whether Amphotericin B increases or decreases the risk of hip fracture. Without this specific information, I cannot 
provide a definitive answer to your question.
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) Your task is to answer questions about various documents.
You will be given various passages from these documents, and asked to answer questions 
about them, or summarize them into coherent answers.
 (FDAHandler)  Entity.USER 
*(FDAHandler)  Entity.AGENT  Entity.AGENT(DocumentHandler) (=>          ) (X           )       (          ) 
                Do one of the following:
                1. Search for relevant text using one of the following tools/functions:
                    `relevant_extracts`, `relevant_search_extracts`, and `drug_category_search`
                2. If you could not find an answer, state that you are done and DO-NOT-KNOW
                    as usual
                3. If you have found an answer, state that you are done and express the answer
                    as usual
                4. If you have no clear remaining question to answer, answer the original
                    question as in #3, and if there was no original question, respond
                    as in #2

                If you have been getting or sending repeated messages, always exit by
                stating that you are done (using the usual code) and say DO-NOT-KNOW.

                DO NOT simply acknowldedge these instructions. If you have nothing
                else to say, you are done and you MUST EXIT IMMEDIATELY by stating that you are done
                with the usual code (you MUST choose #2 or #3, and #4 specifies how to choose).
                THIS IS VERY IMPORTANT. DO THIS IMMEDIATELY BEFORE WAITING FOR ANY FURTHER MESSAGES.
                
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) DO-NOT-KNOW
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT 
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does AMPHOTERICIN B increase or decrease the risk of hip fracture?",
    "steps": [
      "I attempted to obtain information regarding the effect of Amphotericin B on the risk of hip fracture by consulting FDAHandler.",
      "There was no response from FDAHandler, which prevents me from providing a reliable answer based on FDA label data."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-hip fracture-AMPHOTERICIN B)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does AMPHOTERICIN B increase or decrease the risk of hip fracture?",
    "steps": [
      "I attempted to obtain information regarding the effect of Amphotericin B on the risk of hip fracture by consulting FDAHandler.",
      "There was no response from FDAHandler, which prevents me from providing a reliable answer based on FDA label data."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does AMPHOTERICIN B increase or decrease the risk of hip fracture?
        -----
        Reasoning:
        1. I attempted to obtain information regarding the effect of Amphotericin B on the risk of hip fracture by consulting FDAHandler.
2. There was no response from FDAHandler, which prevents me from providing a reliable answer based on FDA label data.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": ""
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-hip fracture-AMPHOTERICIN B)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "",
    "request": "feedback"
  }
}
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) Your reasoning is valid, no feedback was provided.
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.USER 
 (orchestrator-hip fracture-AMPHOTERICIN B)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-hip fracture-AMPHOTERICIN B)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

The question was whether Amphotericin B increases or decreases the risk of hip fracture. I attempted to obtain this information from FDAHandler, but there was no response. Without specific data from 
the FDA label, I cannot provide a reliable answer. Therefore, the final answer is DO-NOT-KNOW, as the FDA label data does not specify the effect of Amphotericin B on the risk of hip fracture.
